133 related articles for article (PubMed ID: 6416848)
1. Correlation between inhibitory effect on prolactin secretion and antitumor activity of new ergoline compounds on DMBA-induced tumors in rats.
Formelli F; Zaccheo T; Di Salle E; Ornati G; Di Marco A
Eur J Cancer Clin Oncol; 1983 Nov; 19(11):1545-51. PubMed ID: 6416848
[TBL] [Abstract][Full Text] [Related]
2. Combined and sequential treatment using FCE 21336, a new prolactin-lowering drug, and medroxyprogesterone acetate (MPA) in DMBA-induced tumors in rats.
Zaccheo T; Casazza AM; di Salle E; Pollini C; di Marco A
Eur J Cancer Clin Oncol; 1984 Sep; 20(9):1193-7. PubMed ID: 6236980
[TBL] [Abstract][Full Text] [Related]
3. Comparative effects of a series of prolactin inhibitors, 17beta-estradiol and 2alpha-methyldihydrotestosterone propionate, on growth of 7,12-dimethylbenz(a)anthracene-induced rat mammary carcinomas.
Teller MN; Stock CC; Hellman L; Mountain IM; Bowie M; Rosenberg BJ; Boyar RM; Budinger JM
Cancer Res; 1977 Nov; 37(11):3932-8. PubMed ID: 409489
[TBL] [Abstract][Full Text] [Related]
4. A new irreversible aromatase inhibitor, 6-methylenandrosta-1,4-diene-3,17-dione (FCE 24304): antitumor activity and endocrine effects in rats with DMBA-induced mammary tumors.
Zaccheo T; Giudici D; Lombardi P; di Salle E
Cancer Chemother Pharmacol; 1989; 23(1):47-50. PubMed ID: 2491793
[TBL] [Abstract][Full Text] [Related]
5. Influence of prolactin and growth hormone on rat mammary tumors induced by N-nitrosomethylurea.
Rose DP; Noonan JJ
Cancer Res; 1982 Jan; 42(1):35-8. PubMed ID: 6797725
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of FCE 21336, a new prolactin lowering drug, on the MXT mouse mammary carcinoma.
Zaccheo T
Cancer Lett; 1985 Sep; 28(2):237-41. PubMed ID: 4052994
[TBL] [Abstract][Full Text] [Related]
7. Activity of 6-methyl-8-substituted ergolines against the 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma.
Sweeney MJ; Poore GA; Kornfeld EC; Bach NJ; Owen NV; Clemens JA
Cancer Res; 1975 Jan; 35(1):106-9. PubMed ID: 1109784
[TBL] [Abstract][Full Text] [Related]
8. Potent inhibitory activity of a new antiestrogen, RU 16 117, on the development and growth of DMBA-induced rat mammary adenocarcinoma.
Labrie F; Kelly PA; Asselin J; Raynaud JP
Recent Results Cancer Res; 1976; (57):109-20. PubMed ID: 827798
[TBL] [Abstract][Full Text] [Related]
9. Potent inhibitory effect of a new antiestrogen (RU 16117) on the growth of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors.
Kelly PA; Asselin J; Caron MG; Labrie F; Raynaud JP
J Natl Cancer Inst; 1977 Mar; 58(3):623-8. PubMed ID: 402479
[TBL] [Abstract][Full Text] [Related]
10. Effects of bromocriptine and tamoxifen on growth and hormone receptor levels of 7,12-dimethylbenz(a)anthracene-induced mammary tumors in rats.
Waseda N; Kato Y; Matsushita N; Imura H
Endocrinol Jpn; 1983 Aug; 30(4):529-35. PubMed ID: 6323151
[TBL] [Abstract][Full Text] [Related]
11. Prolactin secretion inhibition by a new 8alpha-amino-ergoline, CH 29-171.
Flückiger E; Briner U; Doepfner W; Kovacs E; Marbach P; Wagner HR
Experientia; 1978 Oct; 34(10):1330-2. PubMed ID: 570121
[No Abstract] [Full Text] [Related]
12. Prolactin binding to mammary gland, 7,12-dimethylbenz(a)-anthracene-induced mammary tumors, and liver in rats.
Smith RD; Hilf R; Senior AE
Cancer Res; 1976 Oct; 36(10):3726-31. PubMed ID: 821605
[TBL] [Abstract][Full Text] [Related]
13. Effect of the irreversible aromatase inhibitor FCE 24304 on DMBA-induced mammary tumors in ovariectomized rats treated with testosterone.
Zaccheo T; Di Salle E
Cancer Chemother Pharmacol; 1989; 25(2):95-8. PubMed ID: 2513137
[TBL] [Abstract][Full Text] [Related]
14. Is there any association between the pharmacologic control of prolactin release and its action on mammary carcinogenesis in the rat?
Feuer G; Kellen JA; Kovacs K
Clin Endocrinol (Oxf); 1977; 6 Suppl():57S-63S. PubMed ID: 101323
[TBL] [Abstract][Full Text] [Related]
15. The prophylaxis of rat and mouse mammary gland tumorigenesis by suppression of prolactin secretion: a reappraisal.
Welsch CW; Goodrich-Smith M; Brown CK; Roth L
Breast Cancer Res Treat; 1981; 1(3):225-32. PubMed ID: 6816317
[TBL] [Abstract][Full Text] [Related]
16. Interactions between estrogens, prolactin, and growth hormone on the growth of N-nitrosomethylurea-induced rat mammary tumors.
Rose DP; Gottardis M
Anticancer Res; 1985; 5(4):397-402. PubMed ID: 4037735
[TBL] [Abstract][Full Text] [Related]
17. Influence of thyroidectomy and prolactin suppression on the growth of N-nitrosomethylurea-induced rat mammary carcinomas.
Rose DP; Mountjoy KG
Cancer Res; 1983 Jun; 43(6):2588-91. PubMed ID: 6850579
[TBL] [Abstract][Full Text] [Related]
18. Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels.
Clemens JA; Bennett DR; Black LJ; Jones CD
Life Sci; 1983 Jun; 32(25):2869-75. PubMed ID: 6406781
[TBL] [Abstract][Full Text] [Related]
19. Ergolines as potential prolactin and mammary tumor inhibitors.
Cassady JM; Floss HG
Lloydia; 1977; 40(1):90-106. PubMed ID: 327183
[No Abstract] [Full Text] [Related]
20. Antitumor activity of the aromatase inhibitor FCE 24928 on DMBA-induced mammary tumors in ovariectomized rats treated with testosterone.
Zaccheo T; di Salle E
Cancer Chemother Pharmacol; 1993; 31(4):308-12. PubMed ID: 8422695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
